Stockscreener 앱 받기
7.36
2.77%
-0.21
시간 외 거래:
7.36
전일 마감가:
$7.57
열려 있는:
$7.49
하루 거래량:
736.02K
Relative Volume:
1.30
시가총액:
$477.27M
수익:
-
순이익/손실:
$-36.95M
주가수익비율:
-8.00
EPS:
-0.92
순현금흐름:
$-33.46M
1주 성능:
-5.40%
1개월 성능:
+10.68%
6개월 성능:
-5.22%
1년 성능:
+130.36%
1일 변동 폭
$7.20
$7.59
1주일 범위
$7.20
$8.77
52주 변동 폭
$2.18
$13.68
Larimar Therapeutics Inc Stock (LRMR) Company Profile
명칭
Larimar Therapeutics Inc
전화
844-511-9056
주소
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-19 | 개시 | Guggenheim | Buy |
| 2022-02-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 개시 | JMP Securities | Mkt Outperform |
| 2021-02-01 | 개시 | William Blair | Outperform |
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat
Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com
Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Receives "Buy" Rating from HC Wainwright - MarketBeat
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN
Larimar Therapeutics Q3 2024 Financial Update - TipRanks
Larimar: Q3 Earnings Snapshot - CTPost
Larimar Therapeutics (NASDAQ:LRMR) Shares Gap UpShould You Buy? - MarketBeat
Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire
(LRMR) Investment Analysis and Advice - Stock Traders Daily
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Trading Up 6.8%Here's Why - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Now Covered by Analysts at Oppenheimer - Defense World
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth - Yahoo Finance
Larimar initiated with bullish view at Oppenheimer on lead drug - MSN
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga
Larimar stock gets bullish view at Oppenheimer (LRMR:NASDAQ) - Seeking Alpha
Oppenheimer Begins Coverage on Larimar Therapeutics (NASDAQ:LRMR) - MarketBeat
(LRMR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Millennium Management LLC Boosts Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics Inc (LRMR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
An Analysis of Larimar Therapeutics Inc (LRMR)’s Potential Price Growth - Knox Daily
Larimar Therapeutics Inc (LRMR) Stock: A Year of Highs and Lows - The InvestChronicle
Hopeful Week For Insiders Who Bought US$540.7k Of Larimar Therapeutics Stock - Simply Wall St
Technical analysis of Larimar Therapeutics Inc (LRMR) stock chart patterns - US Post News
Financial Metrics Unveiled: Larimar Therapeutics Inc (LRMR)’s Key Ratios in the Spotlight - The Dwinnex
Analysts Offer Predictions for Larimar Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential - Seeking Alpha
How To Trade (LRMR) - Stock Traders Daily
Larimar Therapeutics Inc [LRMR] Shares Rise 3.66 % on Thursday - Knox Daily
Quarry LP Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Expected to Earn Q3 2024 Earnings of ($0.37) Per Share - MarketBeat
Anchoring Your Portfolio: Is LRMR Stock a Safe Harbor? - The InvestChronicle
Larimar started at outperform by Wedbush on FA drug candidate (NASDAQ:LRMR) - Seeking Alpha
Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated at Wedbush - MarketBeat
Holdings of Larimar Therapeutics Inc (LRMR) are aligned with the stars - SETE News
Point72 Asset Management L.P. Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Renaissance Technologies LLC Trims Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Now Covered by HC Wainwright - MarketBeat
HC Wainwright & Co. Initiates Coverage of Larimar Therapeutics (LRMR) with Buy Recommendation - MSN
Understanding the Risks of Investing in Larimar Therapeutics Inc (LRMR) - Knox Daily
Is Larimar Therapeutics Inc (LRMR) a good investment opportunity? - US Post News
Deeper Dive: Understanding Larimar Therapeutics Inc (LRMR) Through its Various Ratios - The Dwinnex
Larimar started at outperform by Wedbush on FA drug candidate - MSN
Larimar Therapeutics' SWOT analysis: nomlabofusp's potential drives stock outlook - Investing.com
Driehaus Capital Management LLC Has $9.53 Million Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics' SWOT analysis: nomlabofusp's potential drives stock outlook By Investing.com - Investing.com UK
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Larimar Therapeutics Inc (LRMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Larimar Therapeutics Inc 주식 (LRMR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Flynn James E | Director |
Feb 16 '24 |
Buy |
8.74 |
4,290,617 |
37,499,993 |
6,151,406 |
| THOMAS FRANK E | Director |
Feb 14 '24 |
Buy |
11.00 |
2,000 |
22,000 |
2,000 |
| Shankar Gopi | Chief Development Officer |
Dec 07 '23 |
Buy |
3.73 |
5,000 |
18,662 |
5,000 |
2.02%
0.47%
자본화:
|
볼륨(24시간):